UniQure NV (QURE) is not a good buy for a beginner investor with a long-term strategy at this time. Despite some positive financial growth trends, the stock faces significant regulatory and legal challenges, bearish technical indicators, and negative sentiment in the market. The lack of strong trading signals and the absence of clear positive catalysts further support a hold recommendation.

Technical Analysis

The technical indicators for QURE are bearish. The MACD is negatively expanding, RSI is neutral at 23.777, and moving averages suggest a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level (S1: 17.904), with resistance levels far above current prices, indicating limited upward momentum in the short term.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Additionally, biotech stocks are generally viewed positively by analysts for 2026, with expectations of M&A activity and strong fundamentals.

Neutral/Negative Catalysts

The stock has faced a significant drop in price due to regulatory concerns over its lead program AMT-130 and multiple class action lawsuits alleging inadequate disclosures. Negative sentiment is further fueled by the FDA's stricter stance on rare disease drug approvals. Technical indicators and trading sentiment are also bearish.

Financial Performance

In Q3 2025, uniQure reported a 61.83% YoY increase in revenue to $3.7M and an 81.46% YoY improvement in net income to -$80.53M. EPS improved by 51.65% YoY to -1.38, and gross margin increased to 89.25%, up 61.22% YoY. Despite these improvements, the company remains unprofitable.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are mixed to cautious on QURE. Wolfe Research initiated coverage with a Peer Perform rating, citing a need for clarity on AMT-130. Barclays gave an Equal Weight rating with a $31 price target, while Stifel and Mizuho lowered price targets to $40 and $33, respectively, citing delays and reduced probability of success for AMT-130.

10 Analyst Rating

Wall Street analysts forecast QURE stock price to rise

8 Buy

2 Hold

0 Sell

Strong Buy

Current: 15.630

Low

Averages

49.88

High

Current: 15.630

Low

Averages

49.88

High

Stifel

maintain

AI Analysis

2026-02-26

New

Reason

Stifel

Price Target

AI Analysis

2026-02-26

New

maintain

Reason

Stifel says that it can see why uniQure's (QURE) shares are lower on CNBC comments from FDA commissioner Marty Makary, where he was interviewed about FDA's approach to rare disease. Makary was defensive of FDA's approach broadly, as he appeared to maybe refer to the AMT-130 program as an example of something his FDA didn't get behind. To be clear, his specific commentary might/might not have been referring to AMT-130 since uniQure never received an actual CRL, the firm notes. Some seem to think Makary was referring to Regenxbio's (RGNX) RGX-121, but this doesn't really make sense to Stifel since he describes a drug that didn't beat a control arm, and the Regenxbio study in Hunter was single-arm. Specific details aside, what's also notable is his steadfast defense of FDA which is discouraging for those hoping that the agency can be convinced to reconsider recent negative decisions, in the absence of specific political pressure, argues the firm.

RBC Capital

Outperform

maintain

$45

2026-02-26

New

Reason

RBC Capital

Price Target

$45

2026-02-26

New

maintain

Outperform

Reason

RBC Capital reiterated an Outperform rating and $45 price target on uniQure shares after the stock is trading down following FDA Commissioner Marty Makary's CNBC appearance on rare disease therapy approvals. While the company was not mentioned by name, the Commissioner's comments referencing researchers drilling holes in patients' skulls appear directed at uniQure's gene therapy approach for Huntington's Disease, the firm told investors in a research note. RBC added that while the news is "disappointing", it is yet to hear a formal announcement from the company.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for QURE

Unlock Now

QURE Should I Buy

QURE Should I Buy

Should You Buy Uniqure NV (QURE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch